Published February 20, 2009
More Transparency for Imported Drugs Sought by FDA
US Pharm. 2008;34(2):6.
-- In an effort to protect patients against imported counterfeit or tainted drugs, the FDA has launched a pilot program requesting drug manufacturers to voluntarily submit more details about their supply chain so that they can get their products across U.S. border entry points more quickly. The program is being instituted because more than 80% of active drug ingredients are produced overseas, and there has been an increase in the number of counterfeit or tainted drugs entering the U.S. Under the pilot program, which is scheduled to run for two years, the FDA will choose 100 applicants that can submit up to five drugs to be pre-approved.
To comment on this article. contact firstname.lastname@example.org.